The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease

Eur Heart J Cardiovasc Pharmacother. 2024 Feb 23;10(2):93-94. doi: 10.1093/ehjcvp/pvad097.

Authors

A Michael Lincoff¹, Donna H Ryan²

Affiliations

¹ Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
² Pennington Biomedical Research Center, Baton Rouge, LA, USA.

PMID: 38066700
DOI: 10.1093/ehjcvp/pvad097

No abstract available

MeSH terms

Cardiovascular Diseases / prevention & control
Clinical Trials as Topic
Diabetes Mellitus
Glucagon-Like Peptides* / therapeutic use
Humans
Obesity* / drug therapy
Overweight* / drug therapy
Secondary Prevention

Substances

Glucagon-Like Peptides
semaglutide

Grants and funding

Novo Nordisk